Cristina Díaz de Heredia

Cristina Díaz de Heredia

Auto-generated profile, based on publicly available information

Cristina Díaz de Heredia

Department of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2011 in Nature Immunology
Verified
Journal Article
Open access
PDF file
IPIrene Puga
Irene Puga
MCMontserrat Cols
Montserrat Cols
CBCarolina M Barra
Carolina M Barra
BHBing He
Bing He
LCLinda Cassis
Linda Cassis
ACAndrea Cerutti
Andrea Cerutti
Follicular T cells provide help to B cells to elicit antibody responses. Cerutti and colleagues show that neutrophils provide help to marginal-zone B cells that produce T cell–independent antibodies. Neutrophils use immunoglobulins to clear antigen, but their role in immunoglobulin production is unknown. Here we identified neutrophils around the marginal zone (MZ) of the spleen, a B cell area specialized in T cell–independent immunoglobulin responses to circulating antigen. Neutrophils colonized peri-MZ areas after postnatal mucosal colonization by microbes and enhanced their B cell–helper function after receiving reprogramming signals, including interleukin 10 (IL-10), from splenic sinusoidal endothelial cells. Splenic neutrophils induced immunoglobulin class switching, somatic hypermutation and antibody production by activating MZ B cells through a mechanism that involved the cytokines BAFF, APRIL and IL-21. Neutropenic patients had fewer and hypomutated MZ B cells and a lower abundance of preimmune immunoglobulins to T cell–independent antigens, which indicates that neutrophils generate an innate layer of antimicrobial immunoglobulin defense by interacting with MZ B cells.

30 April 2014 in Haematologica
Verified
Journal Article
Open access
PDF file
EAEmanuele Angelucci
Emanuele Angelucci
SMS. Matthes-Martin
S. Matthes-Martin
DBD. Baronciani
D. Baronciani
FBF. Bernaudin
F. Bernaudin
SBS. Bonanomi
S. Bonanomi
OPOn Behalf Of The Ebmt Inborn Error And Ebmt Paediatric Working Parties
On Behalf Of The Ebmt Inborn Error And Ebmt Paediatric Working Parties
Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in the world. The outlook for affected individuals has improved in recent years due to advances in medical management in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes today have substantially improved compared with the past three decades. Current experience world-wide is that more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around 80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic stem cell transplantation and transplant management remain principally dependent on data from retrospective analyses and on the clinical experience of the transplant centers. This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management.

1 March 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
FBFederica Barzaghi
Federica Barzaghi
LHLaura Cristina Amaya Hernandez
Laura Cristina Amaya Hernandez
BNBenedicte Neven
Benedicte Neven
SRSilvia Ricci
Silvia Ricci
ZKZeynep Yesim Kucuk
Zeynep Yesim Kucuk
RBRosa Bacchetta
Rosa Bacchetta
Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. This analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors. Clinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed. We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS. Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.

7 April 2011 in Blood
Verified
Journal Article
Open access
PDF file
MCMaria Castella
Maria Castella
RPRoser Pujol
Roser Pujol
ECElsa Callén
Elsa Callén
JTJuan P. Trujillo
Juan P. Trujillo
JCJosé A. Casado
José A. Casado
Jordi SurrallésJordi Surrallés
Jordi Surrallés
Fanconi anemia is characterized by congenital abnormalities, bone marrow failure, and cancer predisposition. To investigate the origin, functional role, and clinical impact of FANCA mutations, we determined a FANCA mutational spectrum with 130 pathogenic alleles. Some of these mutations were further characterized for their distribution in populations, mode of emergence, or functional consequences at cellular and clinical level. The world most frequent FANCA mutation is not the result of a mutational “hot-spot” but results from worldwide dissemination of an ancestral Indo-European mutation. We provide molecular evidence that total absence of FANCA in humans does not reduce embryonic viability, as the observed frequency of mutation carriers in the Gypsy population equals the expected by Hardy-Weinberg equilibrium. We also prove that long distance Alu-Alu recombination can cause Fanconi anemia by originating large interstitial deletions involving FANCA and 2 adjacent genes. Finally, we show that all missense mutations studied lead to an altered FANCA protein that is unable to relocate to the nucleus and activate the FA/BRCA pathway. This may explain the observed lack of correlation between type of FANCA mutation and cellular phenotype or clinical severity in terms of age of onset of hematologic disease or number of malformations.

13 February 2012 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
JSJ Sanz
J Sanz
JBJuan Carlos Hernández Boluda
Juan Carlos Hernández Boluda
CMC Martín
C Martín
MGM González
M González
CFC Ferrá
C Ferrá
O(On Behalf Of Grupo Español de Trasplante Hematopoyético Y Terapia Celular (Geth)
On Behalf Of Grupo Español de Trasplante Hematopoyético Y Terapia Celular (Geth)
Attempts to optimize outcomes in cord blood transplantation (CBT) by using new conditioning regimens and standardization of cord blood unit selection are warranted. In all, 88 patients (18 children and 70 adults) with hematological malignancy from nine Spanish institutions underwent a single-unit CBT after an i.v. BU-based myeloablative conditioning regimen. All evaluable patients except one engrafted. The overall cumulative incidence (CI) of myeloid engraftment was 94% at a median time of 19 days. In multivariate analysis, nonadvanced disease stage was the only factor with a favorable impact on myeloid engraftment. The CI of acute GVHD grades II–IV and chronic extensive GVHD were 24% each. The CI of nonrelapse mortality at 100 days, 180 days and 5 years was 14, 23 and 44%, respectively. The 5-year CI of relapse was 18%, whereas disease-free survival (DFS) was 46%, 39% and 11% for patients transplanted in early, intermediate and advanced stages of the disease, respectively. Our study shows high rates of engraftment with fast neutrophil recovery in patients undergoing single-unit CBT using a BU-based conditioning regimen. Long-term DFS can be achieved in a substantial number of patients with high-risk hematological malignancies, particularly when transplanted in an early stage of the disease.

7 January 2011 in Leukemia
Verified
Journal Article
Closed access
PDF file
BSB Strahm
B Strahm
PNP Nöllke
P Nöllke
MZMarco Zecca
Marco Zecca
EKE T Korthof
E T Korthof
MBM Bierings
M Bierings
FGfor the EWOG-MDS study group
for the EWOG-MDS study group